Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants
Journal of Infection · 2023
DOI: 10.1016/j.jinf.2023.06.024 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Infection, 2023. Verfasst von Mini Kamboj und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infection Control, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Infectious Disease Service, Department of Medicine, Memorial Sloan Kett…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infection Control, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill…
- Infection Control, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Can…
- Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Zitieren
APA
Kamboj, M., Laracy, J. C., Usiak, S., Babady, N. E., Yan, J., & Seo, S. K. (2023). Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants. Journal of Infection. https://doi.org/10.1016/j.jinf.2023.06.024
Vancouver
Kamboj M, Laracy JC, Usiak S, Babady NE, Yan J, Seo SK. Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants. Journal of Infection. 2023. doi:10.1016/j.jinf.2023.06.024
BibTeX
@article{Kamboj2023,
author = {Kamboj, Mini and Laracy, Justin C and Usiak, Shauna and Babady, N Esther and Yan, Judy and Seo, Susan K},
title = {Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants},
journal = {Journal of Infection},
year = {2023},
doi = {10.1016/j.jinf.2023.06.024}
}
EUVIMED